Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

People have got to calm down, news wasn't all that

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154853
(Total Views: 780)
Posted On: 03/30/2022 7:59:20 PM
Posted By: jojopaint57
Re: gestalt2 #121046
People have got to calm down, news wasn't all that catastrophic, in fact I'm encouraged by hiring of Dr. Brunke. Another experienced polished professional on board.

As for the HIV announcement, I thought the PR was a bit incomplete or misleading. One sentence says the FDA "placed a partial clinical hold on it's HIV program" - however in second paragraph it says " the company was not enrolling any new patients in the trials placed on hold AND partial clinical hold on the HIV program impacts patients currently enrolled in extension trials". Clarity, at least for me is needed and expected tomorrow.

The CMC section was submitted on Dec. 1st and the PR stated " CYDY completed submission of all the major sections of CMC module, SOME remaining supporting documentation will be submitted under Regional Information by end of the week". On the shareholders conference call Dr. Ray sounded reassured everything was fine as he knew at the time.

As for Brazil CV-19 trial, they PR'd on 12/8 that the Brazilian "CRO (AEIH) met with ANVISA and received it's AGREEMENT to modify the CD16 trial", thus reducing the patient enrollment from 330 to 126 with interim efficacy analysis by DSMB after 51 patients are enrolled and have completed follow-up to day 28". That was 80 days ago- so maybe results are in fact right around the corner- who knows?

The sky is not falling, lights not being turned out. Management is doing what it should be doing ", evaluating the most OPTIMAL programs on which to focus it's resources & attention". I find Dr. Ray, Dr. Kelly, Dr. Recknor & Antonio Migliarese to be men of integrity and anxious to hear from them tomorrow-


(17)
(1)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us